Literature DB >> 6835396

A survey of human leukaemias for sequences of a human retrovirus.

F Wong-Staal, B Hahn, V Manzari, S Colombini, G Franchini, E P Gelmann, R C Gallo.   

Abstract

Human T-cell leukaemia-lymphoma virus (HTLV) is an exogenous human retrovirus distinct from all known animal retroviruses. HTLV is closely linked to a subtype of adult T-cell malignancies and except for isolated cases, has not been found associated with any other form of leukaemia, lymphoma or other cancers (see refs 1, 2 for review). HTLV can be transmitted to cord blood T lymphocytes in vitro and the infected cells exhibit characteristics of transformed neoplastic T cells. We have recently cloned DNA sequences derived from approximately 1 kilobase (kb) of the 5' and 3' termini of the HTLV genome, as well as a 4-5-kb defective HTLV provirus flanked by cellular sequences. The availability of these probes has enabled us to carry out a limited survey of different fresh or cultured cells from patients of different lymphoid and myeloid malignancies for HTLV-related DNA sequences. The results presented here show that cells from all Japanese patients with adult T-cell leukaemia and several patients with various mature T-cell malignancies from elsewhere contained one or more copies of a highly conserved HTLV genome. The infected cells are of clonal origin. Fresh cells from 1 of the 10 myeloid leukaemic patients contained exogenous DNA sequences distantly related to HTLV.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6835396     DOI: 10.1038/302626a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  45 in total

1.  Complex formation of human T-cell leukemia virus type I p40tax transactivator with cellular polypeptides.

Authors:  K Nagata; Y Ide; T Takagi; K Ohtani; M Aoshima; H Tozawa; M Nakamura; K Sugamura
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

2.  Transcriptional (p40x) and post-transcriptional (p27x-III) regulators are required for the expression and replication of human T-cell leukemia virus type I genes.

Authors:  J Inoue; M Yoshida; M Seiki
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

Review 3.  T-cell control by human T-cell leukemia/lymphoma virus type 1.

Authors:  Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

4.  Transactivation of human T-cell leukemia virus type 1 by herpes simplex virus type 1.

Authors:  S Israel; M Mendelovitz; A Honigman
Journal:  Virus Genes       Date:  1995-02       Impact factor: 2.332

5.  Evaluation of p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met-ethoxy HCl against transplantable and spontaneous murine neoplasia.

Authors:  M J Yagi; J G Bekesi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 6.  Adult T-cell leukemia-lymphoma.

Authors:  S M Neely
Journal:  West J Med       Date:  1989-05

7.  Molecular cloning of a unique human T-cell leukemia virus (HTLV-IIMo).

Authors:  E P Gelmann; G Franchini; V Manzari; F Wong-Staal; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

8.  Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease.

Authors:  M Yoshida; M Seiki; K Yamaguchi; K Takatsuki
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

9.  Chromosomal localization of HTLV-1 viral integration sites using in situ hybridization: detection of a novel IL2R fragment.

Authors:  M J Macera; P Szabo; R S Verma
Journal:  Mol Gen Genet       Date:  1992-09

10.  Genomes of evolutionarily divergent members of the human T-cell leukemia virus family (HTLV-I and HTLV-II) are highly conserved, especially in pX.

Authors:  G M Shaw; M A Gonda; G H Flickinger; B H Hahn; R C Gallo; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.